Vigdis Stefansdottir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vigdis Stefansdottir has a total of 358 co-authors. Here are the top co-authors by number of shared publications:
- Angus Clarke
Institute of Medical Genetics, Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK
9 shared publications Emmanuelle Rial-Sebbag
CERPOP, Bioethics team, Inserm, Université de Toulouse, Toulouse, France
8 shared publicationsSabine Hentze
Synlab, Practice for Human Genetics, Heidelberg, Germany
8 shared publications- Carla G. van El
Department of Human Genetics, Amsterdam UMC, location Vrije Universiteit, Amsterdam, the Netherlands.
7 shared publications Christophe Cordier
Sonic Suisse SA, Genesupport, Lausanne, Switzerland
7 shared publications- Guido de Wert
Department of Health, Ethics and Society, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands
7 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Springer Nature in Journal of Community Genetics
- Vol. 17 (3) , 55
Meeting the demand: A collaborative approach in developing genetic counselling education in the Nordic countries
This program report describes the establishment of the Nordic Network for Genetic Counselling (NNGC) and the ongoing work toward developing a joint Nordic MSc in Genetic Counselling and increasing awareness of genetic counselling in the Nordic countries. Founded officially in 2024, the NNGC brings together universities and university hospitals across the Nordic region and draws on members varied clinical and academic backgrounds. With financial support from NordPlus, the network has built a collaborative framework based on shared responsibility, rotating coordination, and regular digital and in-person meetings. Using the previously EBMG accredited Swedish MSc as a point of reference, the network has a curriculum that aligns with international standards and Nordic priorities related to sustainability, equity, and educational quality. Formal agreements between participating institutions have secured engagement and provided a basis for the development of the master’s programme. The learning points from this collaborative work, including key facilitators, identified barriers, and recommendations when pursuing similar initiatives are presented. Although still under development, the planned Nordic MSc, expected to launch in 2027, demonstrates how regional/international collaboration can strengthen specialized education and support the future workforce needs of precision medicine.
- 1 May 2026
- Published by Springer Nature in Journal of Community Genetics
- Vol. 17 (3) , 55
Open AccessMeeting the demand: A collaborative approach in developing genetic counselling education in the Nordic countries
This program report describes the establishment of the Nordic Network for Genetic Counselling (NNGC) and the ongoing work toward developing a joint Nordic MSc in Genetic Counselling and increasing awareness of genetic counselling in the Nordic countries. Founded officially in 2024, the NNGC brings together universities and university hospitals across the Nordic region and draws on members varied clinical and academic backgrounds. With financial support from NordPlus, the network has built a collaborative framework based on shared responsibility, rotating coordination, and regular digital and in-person meetings. Using the previously EBMG accredited Swedish MSc as a point of reference, the network has a curriculum that aligns with international standards and Nordic priorities related to sustainability, equity, and educational quality. Formal agreements between participating institutions have secured engagement and provided a basis for the development of the master’s programme. The learning points from this collaborative work, including key facilitators, identified barriers, and recommendations when pursuing similar initiatives are presented. Although still under development, the planned Nordic MSc, expected to launch in 2027, demonstrates how regional/international collaboration can strengthen specialized education and support the future workforce needs of precision medicine.
- Open Access
- 14 December 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (2) , 171-184
Cascade counselling and testing. Recommendations of the European Society of Human Genetics
Cascade testing (CT) is an effective instrument for identifying an index patient’s relatives at high risk of a heritable condition enabling informed decision-making on preventive interventions and reproductive choice. However, CT remains underutilised and faces barriers. Discussions are ongoing on how to optimise informing family members and testing uptake in a responsible manner. The European Society of Human Genetics (ESHG) contributes to this debate and provides recommendations based on an ethical analysis of when CT is justified, or may be less compelling, considering proportionality and the judicious use of finite resources. ESHG underscores the strong consensus regarding the ‘moral architecture’ of CT in cases of a high risk of serious, avoidable harm. In such cases, a more active approach towards CT is suggested, including a more directive approach in counselling, more active support for the proband, direct contacting, and balancing confidentiality when this is necessary to avoid a high risk of serious harm, taking account of national regulations and jurisdictions. In contrast, more caution is advised in more complex cases where the balance of benefits and harms of CT is less clear, such as when penetrance is low, and actionability or medical treatment is limited. This more cautious approach does not call for directivity, direct contact or the relaxing of medical confidentiality. The focus, then, shifts to cascade counselling, rather than cascade testing. In some cases, CT may not be proportional or appropriate given the balance between benefits and harms, also in view of available resources.
- 14 December 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 34 (2) , 171-184
Open AccessCascade counselling and testing. Recommendations of the European Society of Human Genetics
Cascade testing (CT) is an effective instrument for identifying an index patient’s relatives at high risk of a heritable condition enabling informed decision-making on preventive interventions and reproductive choice. However, CT remains underutilised and faces barriers. Discussions are ongoing on how to optimise informing family members and testing uptake in a responsible manner. The European Society of Human Genetics (ESHG) contributes to this debate and provides recommendations based on an ethical analysis of when CT is justified, or may be less compelling, considering proportionality and the judicious use of finite resources. ESHG underscores the strong consensus regarding the ‘moral architecture’ of CT in cases of a high risk of serious, avoidable harm. In such cases, a more active approach towards CT is suggested, including a more directive approach in counselling, more active support for the proband, direct contacting, and balancing confidentiality when this is necessary to avoid a high risk of serious harm, taking account of national regulations and jurisdictions. In contrast, more caution is advised in more complex cases where the balance of benefits and harms of CT is less clear, such as when penetrance is low, and actionability or medical treatment is limited. This more cautious approach does not call for directivity, direct contact or the relaxing of medical confidentiality. The focus, then, shifts to cascade counselling, rather than cascade testing. In some cases, CT may not be proportional or appropriate given the balance between benefits and harms, also in view of available resources.
- Open Access
- 8 September 2023
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (1) , 44-51
A population-based survey of FBN1 variants in Iceland reveals underdiagnosis of Marfan syndrome
Marfan syndrome (MFS) is an autosomal dominant condition characterized by aortic aneurysm, skeletal abnormalities, and lens dislocation, and is caused by variants in the FBN1 gene. To explore causes of MFS and the prevalence of the disease in Iceland we collected information from all living individuals with a clinical diagnosis of MFS in Iceland (n = 32) and performed whole-genome sequencing of those who did not have a confirmed genetic diagnosis (27/32). Moreover, to assess a potential underdiagnosis of MFS in Iceland we attempted a genotype-based approach to identify individuals with MFS. We interrogated deCODE genetics’ database of 35,712 whole-genome sequenced individuals to search for rare sequence variants in FBN1. Overall, we identified 15 pathogenic or likely pathogenic variants in FBN1 in 44 individuals, only 22 of whom were previously diagnosed with MFS. The most common of these variants, NM_000138.4:c.8038 C > T p.(Arg2680Cys), is present in a multi-generational pedigree, and was found to stem from a single forefather born around 1840. The p.(Arg2680Cys) variant associates with a form of MFS that seems to have an enrichment of abdominal aortic aneurysm, suggesting that this may be a particularly common feature of p.(Arg2680Cys)-associated MFS. Based on these combined genetic and clinical data, we show that MFS prevalence in Iceland could be as high as 1/6,600 in Iceland, compared to 1/10,000 based on clinical diagnosis alone, which indicates underdiagnosis of this actionable genetic disorder.
- 8 September 2023
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (1) , 44-51
Open AccessA population-based survey of FBN1 variants in Iceland reveals underdiagnosis of Marfan syndrome
Marfan syndrome (MFS) is an autosomal dominant condition characterized by aortic aneurysm, skeletal abnormalities, and lens dislocation, and is caused by variants in the FBN1 gene. To explore causes of MFS and the prevalence of the disease in Iceland we collected information from all living individuals with a clinical diagnosis of MFS in Iceland (n = 32) and performed whole-genome sequencing of those who did not have a confirmed genetic diagnosis (27/32). Moreover, to assess a potential underdiagnosis of MFS in Iceland we attempted a genotype-based approach to identify individuals with MFS. We interrogated deCODE genetics’ database of 35,712 whole-genome sequenced individuals to search for rare sequence variants in FBN1. Overall, we identified 15 pathogenic or likely pathogenic variants in FBN1 in 44 individuals, only 22 of whom were previously diagnosed with MFS. The most common of these variants, NM_000138.4:c.8038 C > T p.(Arg2680Cys), is present in a multi-generational pedigree, and was found to stem from a single forefather born around 1840. The p.(Arg2680Cys) variant associates with a form of MFS that seems to have an enrichment of abdominal aortic aneurysm, suggesting that this may be a particularly common feature of p.(Arg2680Cys)-associated MFS. Based on these combined genetic and clinical data, we show that MFS prevalence in Iceland could be as high as 1/6,600 in Iceland, compared to 1/10,000 based on clinical diagnosis alone, which indicates underdiagnosis of this actionable genetic disorder.
- Open Access
- 19 December 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (3) , 368
Correction to: Reply to Letter by Tellier et al., ‘Scientific refutation of ESHG statement on embryo selection’
- 19 December 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (3) , 368
Open AccessCorrection to: Reply to Letter by Tellier et al., ‘Scientific refutation of ESHG statement on embryo selection’
- Open Access
- 1 December 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (3) , 279-281
Reply to Letter by Tellier et al., ‘Scientific refutation of ESHG statement on embryo selection’
- 1 December 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 31 (3) , 279-281
Open AccessReply to Letter by Tellier et al., ‘Scientific refutation of ESHG statement on embryo selection’
- Open Access
- 11 October 2022
- Published by Springer Nature in Research Square
A population-based survey of FBN1 variants in Iceland reveals underdiagnosis Marfan syndrome
Marfan syndrome is an autosomal dominant condition characterized by aortic aneurysm, skeletal abnormalities, and lens dislocation, and is caused by mutations in the FBN1 gene. To explore causes of Marfan syndrome and the prevalence in Iceland we collected samples and information from all living individuals with a clinical diagnosis of Marfan syndrome in Iceland (n = 35) and performed whole-genome sequencing of those who did not have a confirmed genetic diagnosis. Moreover, to assess a potential underdiagnosis of Marfan syndrome in Iceland we attempted a genotype-based approach for identifying individuals with Marfan syndrome. We interrogated deCODE genetics’ database of 35,712 whole-genome sequenced individuals to search for rare sequence variants in FBN1. Overall, we identified 15 pathogenic or likely pathogenic variants in FBN1 in 41 living individuals, only 22 of whom were previously diagnosed with Marfan syndrome. The most common of these variants, NM_000138.4:c.8038C > T (p.Arg2680Cys), is present in a multi-generational pedigree, and was found to stem from a single forefather born around 1840. The p.Arg2680Cys associates with a form of Marfan syndrome that seems to have an enrichment of abdominal aortic aneurysm, suggesting that this may be a particularly common feature of p.Arg2680Cys-associated Marfan syndrome. Based on these combined genetic and clinical data, we estimate a Marfan syndrome prevalence of at least 1/6,000 in Iceland, compared to 1/10,000 based on clinical diagnosis alone, which indicates underdiagnosis of this actionable genetic disorder.
- 11 October 2022
- Published by Springer Nature in Research Square
Open AccessA population-based survey of FBN1 variants in Iceland reveals underdiagnosis Marfan syndrome
Marfan syndrome is an autosomal dominant condition characterized by aortic aneurysm, skeletal abnormalities, and lens dislocation, and is caused by mutations in the FBN1 gene. To explore causes of Marfan syndrome and the prevalence in Iceland we collected samples and information from all living individuals with a clinical diagnosis of Marfan syndrome in Iceland (n = 35) and performed whole-genome sequencing of those who did not have a confirmed genetic diagnosis. Moreover, to assess a potential underdiagnosis of Marfan syndrome in Iceland we attempted a genotype-based approach for identifying individuals with Marfan syndrome. We interrogated deCODE genetics’ database of 35,712 whole-genome sequenced individuals to search for rare sequence variants in FBN1. Overall, we identified 15 pathogenic or likely pathogenic variants in FBN1 in 41 living individuals, only 22 of whom were previously diagnosed with Marfan syndrome. The most common of these variants, NM_000138.4:c.8038C > T (p.Arg2680Cys), is present in a multi-generational pedigree, and was found to stem from a single forefather born around 1840. The p.Arg2680Cys associates with a form of Marfan syndrome that seems to have an enrichment of abdominal aortic aneurysm, suggesting that this may be a particularly common feature of p.Arg2680Cys-associated Marfan syndrome. Based on these combined genetic and clinical data, we estimate a Marfan syndrome prevalence of at least 1/6,000 in Iceland, compared to 1/10,000 based on clinical diagnosis alone, which indicates underdiagnosis of this actionable genetic disorder.
- Open Access
- 19 August 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 30 (11) , 1306
Correction: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
- 19 August 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 30 (11) , 1306
Open AccessCorrection: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
- Open Access
- 14 March 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 30 (5) , 628
Correction: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
- 14 March 2022
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 30 (5) , 628
Open AccessCorrection: The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
- Open Access
- 17 December 2021
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 30 (5) , 493-495
The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.
- 17 December 2021
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 30 (5) , 493-495
Open AccessThe use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice
Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.